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Introduction
An astonishing volume of 
material has been published about 
Alzheimer’s disease in recent years. 
Typing the word “Alzheimer’s” 
into Google will reward you with 
13,600,000 “results” in 0.15 seconds, 
and a PubMed search of the same 
instantly yields over 55,000 journal 
articles. Yet, primary care physicians 
(PCPs) who regularly see patients 
with Alzheimer’s and related 
dementias know that huge gaps 
exist in our knowledge and our 
ability to provide optimal care. 
Neurologists, geriatricians, and 
psychiatrists may be perceived as 
the physicians who most often care 
for Alzheimer’s patients, but there 
is no doubt that it is generalist PCPs 
who are providing the bulk of the 
care of Alzheimer’s patients. In a 
survey of PCPs in West Virginia 
conducted by the Outreach Program 
of the Blanchette Rockefeller 
Neurosciences Institute (BRNI) in 
mid-2009, 99% of respondents said 
that they see at least one patient per 
month with Alzheimer’s disease or a 
related dementia, and a full 31% said 
that they see 16 or more monthly. 
Demographics alone make it likely 
that virtually every PCP in the state 
will see more than four Alzheimer’s 
patients monthly, as there are 
perhaps 46,000 victims in WV, and 
approximately 1600 practicing PCPs 
available to take care of them. This 
review is intended to provide PCPs 
with a practical, evidence-based 
framework for approaching the many 
affected patients who will come to 
their offices – a way to stand in the 
clinical gap while scientists work 
furiously searching for the cure. 
Recognition and Screening
Because dementia is by definition 
an indolent disorder, recognition 
of it is a challenge in primary care 
offices, where the focus is often, of 
necessity, one of rapid assessment 
and speedy decision-making. The 
fact that patients may have been 
seeing the same physician for years 
is potentially both a help and a 
hindrance in discernment of the 
subtle findings which signal the 
onset of a dementing illness. These 
changes might be more readily 
apparent in familiar patients, in 
whom PCPs may find the new 
presence of a memory disturbance 
to be relatively obvious; however, 
when a primary care physician has 
become accustomed to looking at 
a particular set of problems in a 
particular patient, one might not even 
notice the onset of the typically very 
nuanced early signs of dementia. So, 
it is worthwhile for PCPs to consider 
a defined set of warning signs or 
clinical hints that a patient may be 
in the early stages of dementia. 
The Alzheimer’s Association 
has recently published an updated 
version of their “10 Warning Signs”, 
a useful document for PCPs to 
review and consider posting in their 
offices. (This can be downloaded 
from www.alz.org .) Widespread 
public dissemination of this list 
will help families and patients 
themselves to decide when they 
should inform their physician of 
concerns about memory. A few other 
clinical warning signs may not be as 
immediately recognized as heralding 
dementia, but should also be heeded 
by physicians. These include: 
The Poor Historian: This time-
honored description of the 
patient who just can’t seem 
to tell a coherent story about 
their medical history may serve 
as be a red flag; if a PCP is 
tempted to note this as a feature 
of a patient’s presentation, a 
follow-up question should 
always be asked - “Could this 
be due to early dementia?”
The Repetitive Caller: If the 
front desk staff notices that a 
patient has called several times 
to check on some aspect of an 
appointment, or if the nurse 
•
•
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reports that the patient called 
multiple times for a refill, the 
physician should “file” this 
information, perhaps even 
literally put a note in the chart 
so it can be considered at the 
patient’s next appointment.
The Unexpectedly Delirious 
Patient: Delirium, especially 
occurring with a relatively 
minor physiologic insult, may 
presage the onset of dementia.
The Patient with a New Best 
Friend: Persons with dementia 
are easy targets for those who 
would exploit them, for monetary 
or other purposes. When a 
patient inexplicably appears at 
the office with someone who 
claims to have befriended them 
or to have begun “helping” 
them, for no obvious reason, 
the clinician would be wise to 
maintain a level of skepticism.
Once a problem is recognized, the 
PCP should screen the patient with a 
standardized instrument to ascertain 
if the problem is a true memory 
disorder. “Screening”, in terms of 
community events or widespread 
screening of asymptomatic 
individuals, is not recommended.1 
Home screening is particularly 
discouraged. However, office-based 
case finding is a necessity, and can 
be accomplished with relatively 
little time commitment and without 
disruption of office routines. A 
multitude of screening instruments 
have been developed and are 
available, but the clinical utility 
of many of them is limited by the 
amount of time or expertise required 
to do the testing accurately. The WV 
Alzheimer’s Outreach and Registry 
Program (AORP) recommends that 
PCPs use the “Mini-Cog” screening 
tool. Briefly this consists of a three 
word recall test and a clock drawing 
exercise, which can be performed by 
any trained person in the office (MA, 
nurse, or physician), and has been 
•
•
demonstrated to require only about 
three minutes to complete.2 (Table 1)
Diagnosis
If a screening test indicates a 
possible dementia, the next step is 
to attempt to firm up a diagnosis. 
There is significant overlap in the 
clinical presentation of Alzheimer’s 
disease, vascular dementia, and 
certain other common dementias, 
and often a patient may have a 
mixed disorder. PCPs realize, and 
must make it clear to the patients 
and families, that no clinically useful 
test currently exists which will 
unequivocally confirm a diagnosis 
of Alzheimer’s disease. Certain tests 
are necessary, though, to rule out 
other causes of dementia, some of 
which may be partially treatable. 
While the history and physical 
examination are critical, findings 
may be non-specific; particularly 
important features are noted in 
Table 2. Likewise, laboratory 
testing need not be extensive, 
but certain critical tests must 
be obtained. (Table 3).
Imaging is recommended by the 
American Academy of Neurology.3 
Depending on what is most readily 
available in the area, and what other 
clinical issues may be present in 
the patient, CT or MRI of the head 
may be ordered. Either will rule out 
certain other unsuspected pathology, 
and can help define the extent of 
vascular changes. PET scanning, 
with either FDG (glucose utilization 
functional scanning) or with 
“Pittsburgh Compound”/ PIB (which 
The test:
Give the patient a list of three simple words. (Example: “ball, flag, tree” 
- or - “apple, penny, table”) Ask the patient to repeat the words so you 
will know they have been heard and understood. Perform a Clock 
Drawing Test. Ask the patient to: draw a circle; put in the numbers 
as on the face of a clock; put in the hands of the clock to show a 
particular time. (Choose a time in which the hands of the clock are 
fairly separated, but not an “easy” time such as 3:00 or 6:00.) Ask the 
patient to recall the three words.
The scoring:
One point for each word recalled (without prompting)
One point for normal clock, zero points for abnormal clock. (It is your 
judgment call as to whether a clock is normal.) 
o Three or four points – not supportive of dementia diagnosis 
o Zero to two points – supportive of dementia diagnosis
•
•
•
Table 1. The “Mini-Cog” Screening Instrument
PE may be, and often is, 
completely normal. Potentially 
abnormal findings include:
Anosmia
“Bewildered” affect, especially 
in later stages
Failure of “One-Leg Standing” 
test [cannot stand 5 seconds 
on one leg]
Numerous “subtle neurologic 
abnormalities” [the presence 
of subtle findings which 
are non-diagnostic in and 
of themselves, including: 
generally diminished DTRs, 
decreased grip strength, 
pronator drift, etc.]
Various speech abnormalities 
involving content or fluency
•
•
•
•
•
Table 2. Physical Examination 
Features of Alzheimer’s Disease
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binds to amyloid), yields imaging 
which best discriminates among 
Alzheimer’s and other dementias, 
and is the imaging modality which 
comes closest to being a “diagnostic” 
test. However, many insurance 
carriers consider it to still be 
“experimental”, and therefore they 
will not cover it. Medicare covers PET 
scanning for dementia diagnosis only 
within the strict boundary of testing 
to differentiate between Alzheimer’s 
and Fronto-Temporal Dementia, 
and only after documentation of 
decline in mental status scores 
over six months or more. 
Other evaluation/diagnosis 
strategies are under development, 
including a skin biopsy technique 
now being studied at BRNI. The 
NIH is involved in a wide-ranging 
study of neuroimaging, which 
likewise is very promising but as 
yet is not complete enough to yield 
definitive recommendations. 
Treatment
Once the PCP is comfortable 
with a diagnosis of Alzheimer’s, 
treatment must be considered, and 
generally, three aspects should be 
addressed – risk factor modification, 
treatment of the disease, and 
treatment of behaviors. (Table 4)
Addressing Risk Factors
Prevention of Alzheimer’s 
cannot be guaranteed at this time, 
because we simply don’t know 
enough about the pathophysiology. 
The best defined risks are roughly 
the same as the known risk 
factors of atherosclerotic disease, 
including hypertension and 
hypercholesterolemia. Recently 
it has been more clearly shown 
that diabetes mellitus4 and heavy 
smoking5 in mid-life are independent 
AD risk factors. Attempting to 
modify Alzheimer’s risk factors 
once the disease is manifest, in 
an attempt to change the course 
of the Alzheimer’s itself, may be 
considered futile, and at this time in 
history, it probably is. However, for 
There is no clinically useful diagnostic test for Alzheimer’s at this time, but 
several tests should be done to rule out other memory-loss disorders:
Complete Blood Count; Complete Chemistry Profile
Thyroid Function Tests
B12 levels
Neuroimaging – CT Scan or MRI of head
Depression Screening
•
•
•
•
•
Table 3. Testing Needed in the Evaluation of Possible Alzheimer’s Disease
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patients in early stages of the disease, 
modest attempts to control risk 
factors are reasonable. Good control 
of hypertension is worthwhile, 
and attaining some control of 
hyperlipidemia and diabetes may be 
useful. “Tight” control of diabetes 
is not indicated due to the risk of 
hypoglycemia, which itself is a 
significant contributor to dementia. 
Protection of the head by use of 
seat belts and assistive devices for 
ambulation should be continued, 
for as long as the patient can 
cooperate. Sepsis confers a three-fold 
increase in the risk of subsequent 
cognitive impairment, and so 
should be aggressively treated.6
Disease Treatment 
Treatment of Alzheimer’s 
Disease itself can be attempted 
with two categories of drugs. The 
cholinesterase inhibitors have 
been available for several years 
and remain the first line choice for 
treatment. These include donezepil, 
galantamine and rivastigmine. The 
second available medication is the 
NMDA receptor blocker menantine, 
which is recommended as an add-on 
to treatment with a cholinesterase 
inhibitor. Outcome of treatment 
with these agents is variable, with an 
occasional patient showing visible 
improvement, but for the most part 
they are given in hopes of slowing 
disease progression. While there is 
still a great deal of controversy as to 
the true benefit of these medications, 
they are currently all we have to 
offer, and most patients and families 
will want a trial of treatment. 
Treatment of Behaviors
Non-pharmacologic approaches 
to controlling adverse behaviors 
must always be attempted before 
drugs are used. Often, improving 
caregivers’ understanding of 
why patients behave the way 
they do may forestall the need 
for medication. The Alzheimer’s 
Association is an excellent resource 
for those seeking information about 
these non-drug approaches. 
Occasionally, however, all 
attempts at non-drug therapy will 
fail, and consideration will have 
to be given to using psychotropic 
medications. PCPs who find 
themselves needing to prescribe 
such medications in demented 
patients should first be sure that 
they are treating the patient and 
not the caregiver. If a behavior, 
hallucination/delusion, or sleep 
disturbance is not a problem for the 
patient, it requires no treatment. If 
the patient is endangered, though, 
by their own behavior, then 
treatment will be necessary, and the 
PCP will have to determine which 
therapeutic class to use based on their 
in-depth knowledge of the patient. 
Occasionally benzodiazepines, 
antidepressants, or mood stabilizers 
will have a place in treatment; 
occasionally there are no options 
left except antipsychotics. Of course 
there are black-box warnings 
Disease-specific rx:
 Cholinesterase Inhibitors (CHEI)
Donepezil (Aricept™) Once daily dosing; long clinical experience
Rivastigmine (Exelon™) Available in transdermal patch
Galantamine (Razadyne™) Multiple dosing options
 NMDA receptor blocker
Memantine (Namenda™) Add-on to CHEI in late stages
Treatment of adverse behaviors:
  Always attempt non-pharmacologic approaches first.
   Various medication classes may have a role in specific cases, including antidepressants, anti-anxiety 
agents, antipsychotics. Must be tailored to patient and closely observed.
Risk factor modification:
   Treatment indicated for primary risk factors including hyperlipidemia, diabetes, hypertension, but “tight” 
control, especially of diabetes, should be avoided once the dementia is clinically manifest.
  Head protection, via fall avoidance and seat belt use, should be emphasized.
Table 4. Treatment Approaches for Alzheimer’s Disease
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on these medications now, if 
they are to be used in dementia, 
and many physicians feel that 
informed consent is necessary. 
A recent meta-analysis supports 
the use of cognitive interventions 
for both behaviors and cognitive/
intellectual decline.7 The 
interventions which have worked, 
however, are specific therapies 
administered by professionals, such 
as “spaced retrieval techniques” and 
“sensorimotor skill stimulation”, 
not the simpler games and puzzles 
often recommended or marketed for 
this purpose. PCPs should inform 
patients and families to remain 
engaged with various activities, 
but should discourage purchase 
of special software or games.
Caregivers
Most of the care of Alzheimer’s 
patients is provided by unpaid family 
caregivers, and very often the care 
must be given full time, with little 
respite for the caregiver. The adverse 
outcomes of caregiver stress are well 
known, and their needs must not 
be overlooked. The WV Bureau of 
Senior Services has two programs 
that may be beneficial for those who 
qualify, “Lighthouse” and “FAIR”, 
but the programs are underfunded, 
and cannot provide services to 
nearly all who need them. Again 
the Alzheimer’s Association, and 
also the WV chapter of the National 
Family Caregivers Association 
(www.thefamilycaregiver.org) 
may be useful resources. 
The Future
Much scientific work is underway 
as we seek a cure for this devastating 
disorder. West Virginia is privileged 
to be home to the Blanchette 
Rockefeller Neurosciences Institute, 
the only privately endowed facility 
in the nation devoted to researching 
this disease, where currently 
numerous studies are underway 
regarding pathology, diagnosis, and 
treatment. An Alzheimer’s Registry 
is also under development at BRNI. 
PCPs will use this more than any 
other group of practitioners and 
BRNI will be providing extensive 
education prior to the registry 
being fully implemented. 
Additionally, though, our 
societal commitment as a nation 
must improve, because currently, 
for each cent that the NIH devotes 
to Alzheimer’s research, we spend 
$3.50 on the care of persons with 
the disease.8 As the nation ages, 
the prevalence of Alzheimer’s 
will continue to increase; we 
simply must have more research 
on both prevention and cure. 
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. Which statement is true regarding screening for dementia?
 a. Large community-based screenings at health fairs are very useful and easy to do. 
	 b.	 	Case-finding,	with	standardized	assessment	tools,	can	be	done	in	a	primary	care	office	without	disruption	of	
patient	flow.	
 c. Screening is not necessary, as the diagnosis is always obvious soon after onset of the disorder.
	 d.	 The	most	efficient	screening	tool	is	the	ADAS-Cog.
.  Two categories of drugs are currently on the market for treatment of Alzheimer’s Disease. Of the two, the one 
recommended for an initial treatment trial is: 
 a. ACE Inhibitor
 b. NMDA receptor blocker
 c. Cholinesterase inhibitor
 d. Antioxidant
.  Special software, games, and activities are currently being marketed as tools for both cognitively normal persons and 
early	dementia	patients	to	use	to	maintain	or	improve	memory	and	cognitive	flexibility.	These	items	are:
 a. Strongly recommended as proven and reliable 
 b. Too simple for even the average Alzheimer’s patient
 c. Equal in effectiveness to cognitive interventions performed by professional therapists
	 d.	 Not	as	effective	as	specific	therapies	such	as	sensorimotor	skill	stimulation.
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